Myostatin and Insulin-Like Growth Factor I: Potential Therapeutic Biomarkers for Pompe Disease

PLoS ONE

Volumn 8, Issue 8, 2013, Pages

  Chien, Yin Hsiu ^a   Han, Der Sheng ^a,b   Hwu, Wuh Liang ^a   Thurberg, Beth L ^d   Yang, Wei Shiung ^a,b,c  

^a NATIONAL TAIWAN UNIVERSITY HOSPITAL   (Taiwan)

^b NATIONAL TAIWAN UNIVERSITY   (Taiwan)

^c NATIONAL TAIWAN UNIVERSITY   (Taiwan)

^d SANOFI   (France)

Author keywords

[No Author keywords available]

Indexed keywords

CREATINE KINASE; FOLLISTATIN; MYOSTATIN; RECOMBINANT GLUCAN 1,4 ALPHA GLUCOSIDASE; SOMATOMEDIN C;

ARTICLE; CASE CONTROL STUDY; CHILD; CLINICAL ARTICLE; CONTROLLED STUDY; ENZYME REPLACEMENT; FEMALE; FOLLOW UP; GLYCOGEN STORAGE DISEASE TYPE 2; HUMAN; HUMAN TISSUE; INFANT; MALE; PRESCHOOL CHILD; PROTEIN BLOOD LEVEL;

ADOLESCENT; ADULT; BIOLOGICAL MARKERS; CASE-CONTROL STUDIES; CHILD; CHILD, PRESCHOOL; ENZYME REPLACEMENT THERAPY; FEMALE; GLYCOGEN STORAGE DISEASE TYPE II; HUMANS; INFANT; INSULIN-LIKE GROWTH FACTOR I; MALE; MYOSTATIN; YOUNG ADULT;

EID: 84881534383     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0071900     Document Type: Article

References (31)

1. Thurberg BL, Lynch Maloney C, Vaccaro C, Afonso K, Tsai AC, et al. (2006) Characterization of pre- and post-treatment pathology after enzyme replacement therapy for Pompe disease. Lab Invest 86: 1208-1220.
2. Kishnani PS, Corzo D, Nicolino M, Byrne B, Mandel H, et al. (2007) Recombinant human acid [alpha]-glucosidase: major clinical benefits in infantile-onset Pompe disease. Neurology 68: 99-109.
3. Nicolino M, Byrne B, Wraith JE, Leslie N, Mandel H, et al. (2009) Clinical outcomes after long-term treatment with alglucosidase alfa in infants and children with advanced Pompe disease. Genet Med 11: 210-219.
4. Chien YH, Lee NC, Thurberg BL, Chiang SC, Zhang XK, et al. (2009) Pompe disease in infants: improving the prognosis by newborn screening and early treatment. Pediatrics 124: e1116-1125.
5. van der Ploeg AT, Clemens PR, Corzo D, Escolar DM, Florence J, et al. (2010) A randomized study of alglucosidase alfa in late-onset Pompe's disease. N Engl J Med 362: 1396-1406.
6. Kishnani PS, Steiner RD, Bali D, Berger K, Byrne BJ, et al. (2006) Pompe disease diagnosis and management guideline. Genet Med 8: 267-288.
7. Young SP, Zhang H, Corzo D, Thurberg BL, Bali D, et al. (2009) Long-term monitoring of patients with infantile-onset Pompe disease on enzyme replacement therapy using a urinary glucose tetrasaccharide biomarker. Genet Med 11: 536-541.
8. Pelosi L, Giacinti C, Nardis C, Borsellino G, Rizzuto E, et al. (2007) Local expression of IGF-1 accelerates muscle regeneration by rapidly modulating inflammatory cytokines and chemokines. FASEB J 21: 1393-1402.
9. Shyu KG, Ko WH, Yang WS, Wang BW, Kuan P, (2005) Insulin-like growth factor-1 mediates stretch-induced upregulation of myostatin expression in neonatal rat cardiomyocytes. Cardiovasc Res 68: 405-414.
10. Liu Y, Heinichen M, Wirth K, Schmidtbleicher D, Steinacker JM, (2008) Response of growth and myogenic factors in human skeletal muscle to strength training. Br J Sports Med 42: 989-993.
11. McPherron AC, Lawler AM, Lee SJ, (1997) Regulation of skeletal muscle mass in mice by a new TGF-beta superfamily member. Nature 387: 83-90.
12. Guernec A, Chevalier B, Duclos MJ, (2004) Nutrient supply enhances both IGF-I and MSTN mRNA levels in chicken skeletal muscle. Domest Anim Endocrinol 26: 143-154.
13. Han DS, Chen YM, Lin SY, Chang HH, Huang TM, et al. (2011) Serum myostatin levels and grip strength in normal subjects and patients on maintenance haemodialysis. Clin Endocrinol (Oxf) 75: 857-863.
14. Wintgens KF, Dschietzig T, Stoeva S, Paulsson M, Armbruster FP, (2012) Plasma myostatin measured by a competitive ELISA using a highly specific antiserum. Clin Chim Acta 413: 1288-1294.
15. Gucev Z, Tasic V, Saranac L, Stobbe H, Kratzsch J, et al. (2012) A novel GH1 mutation in a family with isolated growth hormone deficiency type II. Horm Res Paediatr 77: 200-204.
16. Haidet AM, Rizo L, Handy C, Umapathi P, Eagle A, et al. (2008) Long-term enhancement of skeletal muscle mass and strength by single gene administration of myostatin inhibitors. Proc Natl Acad Sci U S A 105: 4318-4322.
17. Jones G, Wortberg M, Kreissig SB, Bunch DS, Gee SJ, et al. (1994) Extension of the four-parameter logistic model for ELISA to multianalyte analysis. Jl Immunol Methods 177: 1-7.
18. Lynch CM, Johnson J, Vaccaro C, Thurberg BL, (2005) High-resolution light microscopy (HRLM) and digital analysis of Pompe disease pathology. J Histochem Cytochem 53: 63-73.
19. Grimberg A, Cohen P, (2000) Role of insulin-like growth factors and their binding proteins in growth control and carcinogenesis. J Cell Physiol 183: 1-9.
20. Barton ER, Morris L, Musaro A, Rosenthal N, Sweeney HL, (2002) Muscle-specific expression of insulin-like growth factor I counters muscle decline in mdx mice. J Cell Biol 157: 137-148.
21. Dobrowolny G, Giacinti C, Pelosi L, Nicoletti C, Winn N, et al. (2005) Muscle expression of a local Igf-1 isoform protects motor neurons in an ALS mouse model. J Cell Biol 168: 193-199.
22. Lineham JD, Smith RM, Dahlenburg GW, King RA, Haslam RR, et al. (1986) Circulating insulin-like growth factor I levels in newborn premature and full-term infants followed longitudinally. Early Hum Dev 13: 37-46.
23. Kouanda S, Tonglet R, De Coninck V, Doulougou B, Sondo B, et al. (2008) Reference values of IGF-I in children from birth to 5 years of age, in Burkina Faso, using blood samples on filter paper. Growth Horm IGF Res 18: 345-352.
24. Yüksel B, Özbek MN, Mungan NÖ, Darendeliler F, Budan B, et al. (2011) Serum IGF-1 and IGFBP-3 levels in healthy children between 0 and 6 years of age. J Clin Res Pediatr Endocrinol 3: 84-88.
25. Gaussin V, Depre C, (2005) Myostatin, the cardiac chalone of insulin-like growth factor-1. Cardiovasc Res 68: 347-349.
26. Van den Hout JM, Kamphoven JH, Winkel LP, Arts WF, De Klerk JB, et al. (2004) Long-term intravenous treatment of Pompe disease with recombinant human alpha-glucosidase from milk. Pediatrics 113: e448-457.
27. Foley JW, Bercury SD, Finn P, Cheng SH, Scheule RK, et al. (2010) Evaluation of systemic follistatin as an adjuvant to stimulate muscle repair and improve motor function in Pompe mice. Mol Ther 18: 1584-1591.
28. Ueno N, Ling N, Ying SY, Esch F, Shimasaki S, et al. (1987) Isolation and partial characterization of follistatin: a single-chain Mr 35,000 monomeric protein that inhibits the release of follicle-stimulating hormone. Proc Natl Acad Sci U S A 84: 8282-8286.
29. Flanagan JN, Linder K, Mejhert N, Dungner E, Wahlen K, et al. (2009) Role of follistatin in promoting adipogenesis in women. J Clin Endocrinol Metabol 94: 3003-3009.
30. Gajos-Michniewicz A, Piastowska AW, Russell JA, Ochedalski T, (2010) Follistatin as a potent regulator of bone metabolism. Biomarkers 15: 563-574.
31. Sebastiani G, Díaz M, López-Bermejo A, Arranz A, de Zegher F, et al. (2012) Circulating follistatin in the human foetus at term birth. Pediatr Obes 7: 39-43.